Exiqon A/S and Oncotech Inc. have announced that Exiqon will acquire Oncotech for approximately $45 million. Oncotech provides diagnostic tests that help physicians optimize treatment regimens for cancer patients. Exiqon provides a number of products to assist in analyzing gene expression, including microRNA profiling products and services. Through the acquisition, Exiqon and Oncotech will combine their respective expertise to 
develop molecular diagnostic tests based on microRNA biomarkers. The companies expect at least one such test to be available within the coming year.
Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
Comments